Review of iRBD biomarker-positive participants shows higher rates of cognitive and autonomic symptoms compared to healthy controls.
Sleep disorder signals hidden brain changes before official Parkinson's diagnosis
This observational review analyzes data from 197 iRBD participants with positive CSF neuronal alpha-synuclein seed amplification assay and 1…
People with this specific sleep disorder show clear signs of brain changes that happen before doctors officially diagnose Parkinson's diseas…
Review synthesizes genetic and environmental risk factors for dementia with Lewy bodies
Genetic and environmental factors linked to dementia with Lewy bodies
This narrative review examines genetic susceptibility and environmental factors, such as pesticides and air pollution, in the context of dem…
A review suggests genes and exposures like pollution may contribute to dementia with Lewy bodies, though details remain incomplete.
FDA Approves DATSCAN (ioflupane I-123) for Striatal Dopamine Transporter Visualization in Suspected Parkinsonian Syndromes or Dementia with Lewy Bodies
FDA approves new brain imaging drug to help doctors diagnose Parkinson's and similar conditions.
DATSCAN is approved as an adjunct diagnostic for striatal dopamine transporter visualization using SPECT brain imaging in adult patients wit…
FDA approves new brain imaging drug to help doctors diagnose Parkinson's and similar conditions.
Observational review of phenoconversion rates and biomarker alignment in Parkinson's disease genetic cohorts
Do your symptoms match the biology, or is the disease hiding in plain sight?
This observational cohort analysis reviews phenoconversion rates and biomarker alignment in Parkinson's Progression Markers Initiative parti…
In people at genetic risk for Parkinson's, symptoms and biological markers often don't align, with nearly one-third showing advanced brain c…